| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.0094 | 0.9 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | 0.0065 | 0.9 |